Figure 6

Laboratory findings in patients with adjunctive therapy. ADAMTS13 activity and related parameters were determined in patients with severe sepsis with APC treatment (n = 5) and without APC (n = 4) therapy over time. (A) ADAMTS13 activity was diminished at the day of enrollment (range 0.19 to 0.53 u/mL) without significance between subgroups but increased during the course of APC treatment. (B) VWF:Ag ranged between 3.6 to 6.9 U/mL at d 1 with a broad spreading tendency in patients without adjunctive therapy and intermittently decrease in APC-treated patients. (C) VWF:CB (collagen binding) decreased in the APC group (range: 146% to 232%) at the day of enrollment while a moderate variation was observed in the non-APC group. (D) VWF propeptide levels were found enhanced in both groups at d 1 (APC group: 3.4 versus non-APC: 5.9 U/mL, not significant (n.s.)) which decreased over time. However, there was a significant difference from treatment d 4 with respect to d 1. Asterisks indicate significant differences during the patients’ course in comparison to day of enrollment (*P < 0.05).